No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 28 of the 34 quarters in the window, leaving 6 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 16.5x · 10Y median 44.2x · 34th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 35
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T20:09:38.132Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T20:09:38.132Z. Latest historical point 2025-08-08.
The latest delayed quote for X4 Pharmaceuticals, Inc. (XFOR) stock was $2.77 as of Oct 6, 2026, 4:00 PM EDT, down 4.48% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -16.6% · 3-year avg -53.2%/yr · 5-year avg -55.1%/yr
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders.
Biotechnology · Boston, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.18
Revenue Est.
$2.30M
Last Quarter Results
EPS
$-0.13
vs Estimate
$-0.18
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1XFOR | $261.27M | $2.77 | -4.48% | -16.59% | -55.06% | N/A | N/A |
| 2IKT | $261.43M | $1.98 | -1.00% | +20.37% | -29.10% | N/A | vs XFOR |
| 3TLSI | $262.92M | $4.27 | -2.51% | -5.17% | -15.05% | N/A | vs XFOR |
| 4OSUR | $259.56M | $3.77 | -8.27% | +29.09% | -17.56% | -6.51% | vs XFOR |
| 5TMCI | $259.49M | $4.00 | -10.71% | -29.44% | -29.41% | N/A | vs XFOR |
| 6EPRX | $259.14M | $7.74 | -0.06% | +32.30% | N/A | N/A | vs XFOR |
forward FY estimate
N/A
$8.81M
vs Estimate
$2.42M
Consensus Rating
Based on 5 analysts
Average Price Target
$11.60
+318.8% upside
Low
$10.00
Current
$2.77
High
$13.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.19 | $-0.18 | $-0.16 | 3 |
| Quarter ending Dec 2026 | $-0.23 | $-0.19 | $-0.15 | 3 |
| Quarter ending Mar 2027 | $-0.25 | $-0.19 | $-0.12 | 1 |
| Quarter ending Jun 2027 | $-0.25 | $-0.18 | $-0.11 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.69 | $-0.65 | $-0.60 | 4 |
| FY 2027 | $-0.87 | $-0.70 | $-0.53 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.73M | $2.30M | $2.88M | 3 |
| Quarter ending Dec 2026 | $1.71M | $2.28M | $2.85M | 3 |
| Quarter ending Mar 2027 | $1.54M | $2.20M | $2.78M | 1 |
| Quarter ending Jun 2027 | $1.96M | $2.80M | $3.53M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $14.95M | $15.98M | $17.01M | 4 |
| FY 2027 | $9.11M | $11.56M | $14.01M | 4 |
